BOUDRY, Switzerland--( BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23 rdEuropean Hematology Association (EHA) annual meeting in Stockholm, Sweden, from June 14-17, 2018.
Celgene to Present New and Updated Data across a Range of Blood Diseases at EHA 2018
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться